Northwest Biotherapeutics Files Q1 2025 10-Q

Ticker: NWBO · Form: 10-Q · Filed: May 15, 2025 · CIK: 1072379

Northwest Biotherapeutics Inc 10-Q Filing Summary
FieldDetail
CompanyNorthwest Biotherapeutics Inc (NWBO)
Form Type10-Q
Filed DateMay 15, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, financials, biotech

TL;DR

NWBO Q1 2025 10-Q filed. Financials and ops update.

AI Summary

Northwest Biotherapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its business operations. Specific financial figures and operational details are available within the full filing.

Why It Matters

This filing provides investors with a quarterly update on Northwest Biotherapeutics' financial health and operational progress, crucial for understanding the company's trajectory in the biopharmaceutical sector.

Risk Assessment

Risk Level: medium — Biopharmaceutical companies often carry higher risk due to the nature of drug development, regulatory hurdles, and market competition.

Key Numbers

  • $550,000 — Derivative Gain/Loss (Related Party Transaction)
  • $736,000 — Derivative Gain/Loss (Related Party Transaction)

Key Players & Entities

  • NORTHWEST BIOTHERAPEUTICS INC (company) — Filer
  • 20250331 (date) — Reporting Period End Date
  • 20250515 (date) — Filing Date
  • BETHESDA, MD (location) — Business Address
  • 001-35737 (other) — SEC File Number

FAQ

What was the reporting period for this 10-Q filing?

The reporting period for this 10-Q filing was March 31, 2025.

When was this 10-Q filed with the SEC?

This 10-Q was filed on May 15, 2025.

What is the company's primary business address?

The company's business address is 4800 Montgomery Lane, Suite 800, Bethesda, MD 20814.

What is the company's SEC file number?

The company's SEC file number is 001-35737.

What are some of the inputs used for fair value measurements of warrant liability?

Inputs mentioned for fair value measurements of warrant liability include risk-free interest rate, price volatility, expected term, and expected dividend rate.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding NORTHWEST BIOTHERAPEUTICS INC (NWBO).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.